Payment overview · 2025
General Payments
$946.74
53 reported records · 16 companies
Healthcare provider profile · identity verified
Eric Robert Hagood, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ALBERTVILLE, AL · NPI 1205375318
Verified facts
What the public records show
CMS Open Payments records show Eric Robert Hagood, CRNP received $946.74 in general payments during 2025 across 53 reported records.
ABBVIE INC. accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $236.55 | 25.0% | 17 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $98.12 | 10.4% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $92.24 | 9.7% | 6 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $87.56 | 9.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $87.41 | 9.2% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $61.05 | 6.5% | 3 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $52.30 | 5.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.00 | 4.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.34 | 3.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.28 | 3.4% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $25.39 | 2.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.26 | 2.5% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $23.18 | 2.5% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $19.15 | 2.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.61 | 1.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.30 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $946.74 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $124.55 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $109.19 | 11 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $87.56 | 3 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $83.59 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $66.13 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $61.05 | 3 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $58.49 | 3 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $52.30 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $46.74 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.28 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.28 | 2 | 2025 |
Source payment records
|
|||||
| TLANDO Normalized: tlando |
Drug | Antares Pharma, Inc. | $25.39 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $25.39 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.02 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $2.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 90 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 32 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
90 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 64 |
| Ozempic | Semaglutide | 90 | 25 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 88 | 25 |
| Atorvastatin Calcium | Atorvastatin Calcium | 77 | 42 |
| Omeprazole | Omeprazole | 77 | 35 |
| Metformin Hcl | Metformin Hcl | 71 | 20 |
| Losartan Potassium | Losartan Potassium | 69 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 56 | 28 |
| Azithromycin | Azithromycin | 55 | 48 |
| Cefdinir | Cefdinir | 55 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 51 | 24 |
| Gabapentin | Gabapentin | 50 | 28 |
| Lisinopril | Lisinopril | 49 | 22 |
| Ondansetron Odt | Ondansetron | 45 | 31 |
| Fenofibrate | Fenofibrate | 42 | 17 |
| Trazodone Hcl | Trazodone Hcl | 41 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 33 | 14 |
| Clindamycin Hcl | Clindamycin Hcl | 32 | 25 |
| Potassium Chloride | Potassium Chloride | 32 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | 12 |
| Celecoxib | Celecoxib | 31 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 29 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Furosemide | Furosemide | 24 | 14 |
| Meloxicam | Meloxicam | 24 | 13 |
| Montelukast Sodium | Montelukast Sodium | 24 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 23 | 11 |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 21 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | 11 |
| Pregabalin | Pregabalin | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | 11 |
| Valsartan | Valsartan | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Fluconazole | Fluconazole | 16 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | 11 |
| Eliquis | Apixaban | 14 | suppressed |
| Prednisone | Prednisone | 14 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $946.74 · 53 records | ABBVIE INC. | AIRSUPRA, BREZTRI, BRIXADI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, JOURNAVX, Kerendia, MAVYRET, NURTEC ODT, Ozempic, QULIPTA, RELISTOR, REXULTI, Rybelsus, SUBLOCADE, TLANDO, TRELEGY ELLIPTA, TRULANCE, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, XIFAXAN, XYOSTED, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error